Wedbush Downgrades Blueprint Medicines (BPMC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades Blueprint Medicines (BPMC) to Neutral
June 2, 2025 11:59 AM EDTJPMorgan analyst Brian Cheng downgraded Blueprint Medicines (NASDAQ: BPMC) from Overweight to Neutral with a price target of $129.00 (from $130.00).
The analyst comments "Sanofi announced its decision to acquire Blueprint (BPMC) our Top Pick for 2025 this morning. The proposed transaction assigns a 27% premium... More
